Prevalence and outcomes of anemia in cancer: A systematic review of the literature

American Journal of Medicine

Volumn 116, Issue 7 SUPPL. 1, 2004, Pages 11-26

  Knight, Kevin ^a   Wade, Sally ^a   Balducci, Lodovico ^b  

^a Zynx Health   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANGIOGENESIS; BLOOD TRANSFUSION; BONE CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CLINICAL TRIAL; COLON CANCER; CONFERENCE PAPER; CORRELATION ANALYSIS; DISEASE COURSE; DRUG CYTOTOXICITY; HEAD AND NECK CANCER; HEALTH CARE COST; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LITERATURE; LUNG CANCER; MIXED TUMOR; MORBIDITY; MORTALITY; MULTIPLE MYELOMA; NEUROBLASTOMA; NONHODGKIN LYMPHOMA; OVARY CANCER; PANCREAS CANCER; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; SIDE EFFECT; SURVIVAL; UTERINE CERVIX CANCER; VULVA CANCER;

ACTIVITIES OF DAILY LIVING; ANEMIA; BLOOD TRANSFUSION; COMORBIDITY; DISEASE PROGRESSION; ERYTHROPOIETIN; HEALTH STATUS; HEMOGLOBINS; HUMANS; INCIDENCE; NEOPLASM STAGING; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; PREVALENCE; PROGNOSIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS;

EID: 1842577545     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2003.12.008     Document Type: Conference Paper

References (74)

1. Littlewood T.J. The impact of hemoglobin levels on treatment outcomes in patients with cancer. Semin Oncol. 28:(suppl 8):2001;49-53.
2. Coiffier B., Guastalla J.P., Pujade-Lauraine E., Bastit P. Predicting cancer-associated anaemia in patients receiving non-platinum chemotherapy results of a retrospective survey. Eur J Cancer. 37:2001;1617-1623.
3. Spivak J.L. Cancer-related anemia its causes and characteristics. Semin Oncol. 21:(suppl 3):1994;3-8.
4. Bron D., Meuleman N., Mascaux C. Biological basis of anemia. Semin Oncol. 28:(suppl 8):2001;1-6.
5. Henry D.H. Recombinant human erythropoietin treatment of anemic cancer patients. Cancer Pract. 4:1996;180-184.
6. Fyles A.W., Milosevic M., Pintilie M., Syed A., Hill R.P. Anemia, hypoxia and transfusion in patients with cervix cancer a review. Radiother Oncol. 57:2000;13-19.
7. Thomas G.M. Raising hemoglobin an opportunity for increasing survival? Oncology. 63:(suppl 2):2002;19-28.
8. Song S.Z., Sun Y., Wang Y.P., Zhang Z.G., Niu F.E. Secondary hematologic changes in small cell lung cancer and malignant lymphoma. Chin Med J (Engl). 100:1987;97-102.
9. Rassam J.W., Anderson G. Incidence of paramalignant disorders in bronchogenic carcinoma. Thorax. 30:1975;86-90.
10. Harrison L.B., Shasha D., White C., Ramdeen B. Radiotherapy-associated anemia the scope of the problem. Oncologist. 5:(suppl 2):2000;1-7.
11. Harrison L.B., Shasha D., Homel P. Prevalence of anemia in cancer patients undergoing radiotherapy prognostic significance and treatment. Oncology. 63:(suppl 2):2002;11-18.
12. Tchekmedyian N.S. Anemia in cancer patients significance, epidemiology, and current therapy. Oncology (Huntingt). 16:(suppl 10):2002;17-24.
13. Twine R.W., Morris C. Early detection of carcinomas of the right colon role of hemoglobin and mean corpuscular volume. J Natl Med Assoc. 78:1986;187-192.
14. Fass L., Anderson F.W., Young L.E. Delay in diagnosis of carcinoma of right side of colon in patients treated for anemia. Am J Med Sci. 251:1966;255-259.
15. Dunne J.R., Gannon C.J., Osborn T.M., Taylor M.D., Malone D.L., Napolitano L.M. Preoperative anemia in colon cancer assessment of risk factors. Am Surg. 68:2002;582-587.
16. Cappell M.S., Goldberg E.S. The relationship between the clinical presentation and spread of colon cancer in 315 consecutive patients a significant trend of earlier cancer detection from 1982 through 1988 at a university hospital. J Clin Gastroenterol. 14:1992;227-235.
17. Dunphy E.P., Petersen I.A., Cox R.S., Bagshaw M.A. The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 16:1989;1173-1178.
18. Lee W.R., Berkey B., Marcial V., et al. Anemia is associated with decreased survival and increased locoregional failure in patients with locally advanced head and neck carcinoma a secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys. 42:1998;1069-1075.
19. Dubray B., Mosseri V., Brunin F., et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer a prospective study. Radiology. 201:1996;553-558.
20. Grant D.G., Hussain A., Hurman D. Pre-treatment anaemia alters outcome in early squamous cell carcinoma of the larynx treated by radical radiotherapy. J Laryngol Otol. 113:1999;829-833.
21. von Knorring J., Selroos O., Scheinin T.M. Haematologic findings in patients with renal carcinoma. Scand J Urol Nephrol. 15:1981;279-283.
22. Obermair A., Petru E., Windbichler G., et al. Significance of pretreatment serum hemoglobin and survival in epithelial ovarian cancer. Oncol Rep. 7:2000;639-644.
23. Obralic N., Bilenjki D., Bilbija Z. Prognostic importance of anemia related parameters in patients with carcinoma of the cervix uteri. Acta Oncol. 29:1990;199-201.
24. Hefler L., Mayerhofer K., Leibman B., et al. Tumor anemia and thrombocytosis in patients with vulvar cancer. Tumour Biol. 21:2000;309-314.
25. Ratkin G.A., Presant C.A., Weinerman B., Reinhard E.H. Correlation of anemia with infradiaphragmatic involvement in Hodgkin's disease and other malignant lymphomas. CMAJ. 111:1974;924-927.
26. Emanuel D.J., Gelfand M. A survey into the clinical presentation of Hodgkin's disease at Harare Hospital, Salisbury, Rhodesia. J Trop Med Hyg. 78:1975;44-46.
27. Bearman R.M., Pangalis G.A., Rappaport H. Hodgkin's disease, lymphocyte depletion type a clinicopathologic study of 39 patients. Cancer. 41:1978;293-302.
28. Pohl C., Schobert I., Moter A., et al. Serum erythropoietin levels in patients with Hodgkin's lymphoma at the time of diagnosis. Ann Oncol. 3:1992;172-173.
29. Lim E.J., Peh S.C. Bone marrow and peripheral blood changes in non-Hodgkin's lymphoma. Singapore Med J. 41:2000;279-285.
30. Michon J. Incidence of anemia in pediatric cancer patients in Europe results of a large, international survey. Med Pediatr Oncol. 39:2002;448-450.
31. Morrow T.J., Volpe S., Gupta S., Tannous R.E., Fridman M. Anemia of cancer in intermediate-grade non-Hodgkin's lymphoma. South Med J. 95:2002;889-896.
32. Moullet I., Salles G., Ketterer N., et al. Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Ann Oncol. 9:1998;1109-1115.
33. Kyle R.A., Gertz M.A., Witzig T.E., et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 78:2003;21-33.
34. Nielsen O.J., Brandt M., Drivsholm A. The secretory erythropoietin response in patients with multiple myeloma and Waldenstrom's macroglobulinaemia. Scand J Clin Lab Invest. 50:1990;697-703.
35. Hannisdal E., Kildahl-Andersen O., Grottum K.A., Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. Eur J Haematol. 45:1990;198-202.
36. Advani S.H., Soman C.S., Talwalkar G.V., Lyer Y.S., Bhatia H.M. Multiple-myeloma review of 231 cases. Indian J Cancer. 15:1978;55-61.
37. Hill R.S., Wilson J.D. Multiple myeloma. 2. A report on sixty-seven cases. N Z Med J. 67:1968;194-203.
38. Dawson A.A., Ogston D. Factors influencing the prognosis in myelomatosis. Postgrad Med J. 47:1971;635-638.
39. Frommhold H., Guttenberger R., Henke M. The impact of blood hemoglobin content on the outcome of radiotherapy the Freiburg experience. Strahlenther Onkol. 174:(suppl 4):1998;31-34.
40. Fein D.A., Lee W.R., Hanlon A.L., et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol. 13:1995;2077-2083.
41. Reed W.R., Hussey D.H., DeGowin R.L. Implications of the anemia of chronic disorders in patients anticipating radiotherapy. Am J Med Sci. 308:1994;9-15.
42. Overgaard J., Hansen H.S., Jorgensen K., Hjelm Hansen M. Primary radiotherapy of larynx and pharynx carcinoma - an analysis of some factors influencing local control and survival. Int J Radiat Oncol Biol Phys. 12:1986;515-521.
43. Warde P., O'Sullivan B., Bristow R.G., et al. T1/T2 glottic cancer managed by external beam radiotherapy the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys. 41:1998;347-353.
44. van Acht M.J., Hermans J., Boks D.E., Leer J.W. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol. 23:1992;229-235.
45. Tarnawski R., Skladowski K., Maciejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys. 38:1997;1007-1011.
46. Overgaard J., Hansen H.S., Andersen A.P., et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys. 16:1989;1065-1068.
47. Hierlihy P., Jenkin R.D., Stryker J.A. Anemia as a prognostic factor in cancer of the cervix a preliminary report. CMAJ. 100:1969;1100-1102.
48. Alexanian R., Balcerzak S., Bonnet J.D., et al. Prognostic factors in multiple myeloma. Cancer. 36:1975;1192-1201.
49. Chow E., Danjoux C.E., Pataki I., et al. Effect of hemoglobin on radiotherapy response in children with medulloblastoma should patients with a low hemoglobin be transfused? Med Pediatr Oncol. 32:1999;395-397.
50. Leitgeb C., Pecherstorfer M., Fritz E., Ludwig H. Quality of life in chronic anemia of cancer during treatment with recombinant human erythropoietin. Cancer. 73:1994;2535-2542.
51. Ludwig H., Chott A., Fritz E., Krainer M. Increase of bone marrow cellularity during erythropoietin treatment in myeloma. Stem Cells. 13:(suppl 2):1995;77-87.
52. Ludwig H., Fritz E., Leitgeb C., et al. Erythropoietin treatment for chronic anemia of selected hematological malignancies and solid tumors. Ann Oncol. 4:1993;161-167.
53. Rapoport B.L., Falkson H.C., Falkson G. Prognostic factors affecting the survival of patients with multiple myeloma a retrospective analysis of 86 patients. S Afr Med J. 79:1991;65-67.
54. Prognostic features in the third MRC myelomatosis trial. Medical Research Council's Working Party on Leukaemia in Adults. Br J Cancer. 42:1980;831-840.
55. Ludwig H., Sundal E., Pecherstorfer M., et al. Recombinant human erythropoietin for the correction of cancer associated anemia with and without concomitant cytotoxic chemotherapy. Cancer. 76:1995;2319-2329.
56. Ludwig H., Pecherstorfer M., Leitgeb C., Fritz E. Recombinant human erythropoietin for the treatment of chronic anemia in multiple myeloma and squamous cell carcinoma. Stem Cells. 11:1993;348-355.
57. Heiss M.M., Tarabichi A., Delanoff C., et al. Perisurgical erythropoietin application in anemic patients with colorectal cancer a double-blind randomized study. Surgery. 119:1996;523-527.
58. Abels R. Erythropoietin for anaemia in cancer patients. Eur J Cancer. 29:(suppl 2):1993;S2-S8.
59. Abels R.I. Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol. 87:(suppl 1):1992;4-11.
60. Braga M., Gianotti L., Vignali A., et al. Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract. Br J Surg. 82:1995;1637-1640.
61. Dammacco F., Castoldi G., Rodjer S. Efficacy of epoetin alfa in the treatment of anaemia of multiple myeloma [published erratum appears in Br J Haematol. 2001;114:738]. Br J Haematol. 113:2001;172-179.
62. Osterborg A., Brandberg Y., Molostova V., et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 20:2002;2486-2494.
63. Scott S.N., Boeve T.J., McCulloch T.M., et al. The effects of epoetin alfa on transfusion requirements in head and neck cancer patients a prospective, randomized, placebo-controlled study. Laryngoscope. 112:(Pt 1):2002;1221-1229.
64. Osterborg A., Boogaerts M.A., Cimino R., et al. for the European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma. Recombinant human erythropoietin in transfusion- dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma - a randomized multicenter study. Blood. 87:1996;2675-2682.
65. Olsson A.M., Svensson J.H., Sundstrom J., et al. Erythropoietin treatment in metastatic breast cancer - effects on Hb, quality of life and need for transfusion. Acta Oncol. 41:2002;517-524.
66. Quirt I., Robeson C., Lau C.Y., et al. Epoetin alfa therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy. J Clin Oncol. 19:2001;4126-4134.
67. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 34:(suppl 2):1997;13-19.
68. Holzner B., Kemmler G., Greil R., et al. The impact of hemoglobin levels on fatigue and quality of life in cancer patients. Ann Oncol. 13:2002;965-973.
69. Lind M., Vernon C., Cruickshank D., et al. The level of haemoglobin in anaemic cancer patients correlates positively with quality of life. Br J Cancer. 86:2002;1243-1249.
70. Ludwig H., Fritz E., Kotzmann H., et al. Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med. 322:1990;1693-1699.
71. Falkson C.I., Keren-Rosenberg S., Uys A., et al. Recombinant human erythropoietin in the treatment of cancer-related anaemia. Oncology. 51:1994;497-501.
72. Glimelius B., Linne T., Hoffman K., et al. Epoetin beta in the treatment of anemia in patients with advanced gastrointestinal cancer. J Clin Oncol. 16:1998;434-440.
73. Sweeney P.J., Nicolae D., Ignacio L., et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy final report of a randomized, open-labelled, phase II trial. Br J Cancer. 77:1998;1996-2002.
74. Henke M., Bechtold C., Momm F., et al. Blood hemoglobin level may affect radiosensitivity-preliminary results on acutely reacting normal tissues. Int J Radiat Oncol Biol Phys. 48:2000;339-345.